Please assess the completion status of the following clinical trial:

Trial Title: A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. confirmed diagnosis of T2DM~2. Glycated hemoglobin (HbA1c) \>=7.0 and \<=10/0% at Visit 1~3. Metformin therapy (at least 1500 mg/day, BID)~4. age\>=18 at Visit 1~5. body mass index \<=45 kg/m2~Exclusion criteria:~1. estimated creatinine clearance rate (eCCr) \<60 ml/min (Cockcroft-Gault formula) screening and/or run-in~2. a confirmed glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast during placebo run-in

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- empagliflozin (high dose qd) (Type: EXPERIMENTAL): Patients receive Empagliflozin high dose once daily
- empagliflozin (high dose bid) (Type: EXPERIMENTAL): Patients receive Empagliflozin high dose split twice daily
- empagliflozin (low dose qd) (Type: EXPERIMENTAL): Patients receive Empagliflozin low dose once daily
- empagliflozin (low dose bid) (Type: EXPERIMENTAL): Patients receive Empagliflozin low dose split twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive placebo matching Empagliflozin

Based on this trial design, predict the completion outcome and termination type (if applicable).